SG11201805380YA - Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy - Google Patents
Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapyInfo
- Publication number
- SG11201805380YA SG11201805380YA SG11201805380YA SG11201805380YA SG11201805380YA SG 11201805380Y A SG11201805380Y A SG 11201805380YA SG 11201805380Y A SG11201805380Y A SG 11201805380YA SG 11201805380Y A SG11201805380Y A SG 11201805380YA SG 11201805380Y A SG11201805380Y A SG 11201805380YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pennsylvania
- formula
- psma
- philadelphia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Nuclear Medicine (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562273786P | 2015-12-31 | 2015-12-31 | |
| US15/385,490 US10688200B2 (en) | 2015-12-31 | 2016-12-20 | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
| PCT/US2016/068327 WO2017116994A1 (en) | 2015-12-31 | 2016-12-22 | Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805380YA true SG11201805380YA (en) | 2018-07-30 |
Family
ID=59225798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805380YA SG11201805380YA (en) | 2015-12-31 | 2016-12-22 | Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10688200B2 (ko) |
| EP (1) | EP3397968B1 (ko) |
| JP (1) | JP6850027B2 (ko) |
| KR (1) | KR20180098373A (ko) |
| CN (1) | CN108541302B (ko) |
| AU (2) | AU2016380151A1 (ko) |
| CA (1) | CA3010295C (ko) |
| DK (1) | DK3397968T3 (ko) |
| EA (1) | EA201891544A1 (ko) |
| HK (1) | HK1255215A1 (ko) |
| IL (1) | IL260342A (ko) |
| MX (1) | MX2018008168A (ko) |
| SG (1) | SG11201805380YA (ko) |
| WO (1) | WO2017116994A1 (ko) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
| DE202014011600U1 (de) | 2013-10-18 | 2023-05-31 | Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts | Markierte Inhibitoren des prostataspezifischen Membranantigens (PSMA), deren Verwendung als bildgebende Mittel und pharmazeutische Wirkstoffe für die Behandlung von Prostatakrebs |
| US10688200B2 (en) | 2015-12-31 | 2020-06-23 | Five Eleven Pharma Inc. | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
| CN114716387A (zh) | 2016-03-22 | 2022-07-08 | 约翰霍普金斯大学 | 用于前列腺癌的腔内放射疗法的前列腺特异性膜抗原靶向的高亲和力剂 |
| US11491247B2 (en) | 2017-05-02 | 2022-11-08 | Cornell University | Methods and reagents for tumor targeting with greater efficacy and less toxicity |
| WO2018222778A1 (en) * | 2017-05-30 | 2018-12-06 | The Johns Hopkins University | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
| UA126413C2 (uk) | 2017-12-11 | 2022-09-28 | Техніше Універзітет Мюнхен | Ліганди psma для візуалізації та ендорадіотерапії |
| US20190184040A1 (en) * | 2017-12-15 | 2019-06-20 | Wisconsin Alumni Research Foundation | Targeted Macrocyclic Agents for Dual Modality PET and MRI Imaging of Cancer |
| MX2018003175A (es) * | 2018-03-14 | 2019-09-16 | Instituto Nac De Investigaciones Nucleares | 177lu-dota-hynic-ipsma como un radiofarmaco terapeutico dirigido al antigeno prostatico especifico de membrana. |
| CN109438517B (zh) * | 2018-12-27 | 2021-01-08 | 北京久杰净化工程技术有限公司 | 一种与羰基金属核心配位的双功能连接剂的配合物及其制备方法 |
| CN114364405B (zh) * | 2019-04-26 | 2024-07-16 | 五一一制药股份有限公司 | 作为诊断剂和放射性核素治疗剂的前列腺特异性膜抗原(psma)抑制剂 |
| WO2020252598A1 (en) | 2019-06-21 | 2020-12-24 | Provincial Health Services Authority | Radiolabeled compounds targeting the prostate-specific membrane antigen |
| CN115380117A (zh) * | 2020-02-18 | 2022-11-22 | 恩多塞特公司 | 治疗表达psma的癌症的方法 |
| CA3194592A1 (en) * | 2020-10-01 | 2022-04-07 | Neil H. Bander | Methods and compositions for increasing uptake, internalization, and/or retention of small molecule ligands |
| CN112358422B (zh) * | 2020-10-16 | 2023-06-23 | 中国辐射防护研究院 | 一种新型螯合剂nbed的制备方法 |
| WO2022193038A1 (zh) * | 2021-03-17 | 2022-09-22 | 五一一制药股份有限公司 | 一种[18F]AlF标记的PSMA靶向分子探针及其制备方法 |
| CN113372285B (zh) * | 2021-05-28 | 2024-06-18 | 西南医科大学附属医院 | 前列腺特异性膜抗原抑制剂、其放射性核素标记物及制法和应用 |
| CN114436905A (zh) * | 2022-01-24 | 2022-05-06 | 攀枝花学院 | 3-醛基-4-羟基苯乙酸甲酯的纯化方法 |
| CN116514735A (zh) * | 2022-01-30 | 2023-08-01 | 晶核生物医药科技(南京)有限公司 | 一种肽脲素衍生物、含其的药物组合物及其应用 |
| CN114874122A (zh) * | 2022-05-31 | 2022-08-09 | 南京航空航天大学 | 一种新的小分子抑制剂及其制备方法和应用 |
| CN116547293A (zh) * | 2023-02-02 | 2023-08-04 | 北京师范大学 | 一种靶向前列腺特异性膜抗原的放射性金属配合物及其标记配体 |
| CN116507630A (zh) * | 2023-02-14 | 2023-07-28 | 北京师范大学 | 含硝基芳香杂环基团的psma靶向放射性金属配合物及其制备 |
| WO2024169886A1 (zh) * | 2023-02-16 | 2024-08-22 | 无锡诺宇医药科技有限公司 | Psma靶向放射性诊疗一体化药物及其合成和应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1472541T1 (sl) | 2002-01-10 | 2010-12-31 | Univ Johns Hopkins | Prikazovalni agensi in postopek prikazovanja naaladase ali psma |
| EP2350031A2 (en) | 2008-08-20 | 2011-08-03 | Ensemble Therapeutics Corporation | Macrocyclic compounds for inhibition of tumor necrosis factor alpha |
| EP2721039B1 (en) * | 2011-06-15 | 2018-01-10 | Cancer Targeted Technology LLC | Chelated psma inhibitors |
| ES2732060T3 (es) * | 2011-08-05 | 2019-11-20 | Molecular Insight Pharm Inc | Inhibidores radiomarcados del antígeno de membrana específico de la próstata |
| CN113149921A (zh) * | 2011-11-30 | 2021-07-23 | 约翰霍普金斯大学 | 前列腺特异性膜抗原(psma)的同源多价抑制剂和异源多价抑制剂以及其用途 |
| EA201890915A1 (ru) * | 2012-11-15 | 2018-09-28 | Эндосайт, Инк. | Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma |
| ES2648096T3 (es) * | 2013-01-14 | 2017-12-28 | Molecular Insight Pharmaceuticals, Inc. | Radiofármacos a base de triazina y agentes de radioformación de imágenes |
| US10406246B2 (en) | 2013-10-17 | 2019-09-10 | Deutsches Kresbsforschungszentrum | Double-labeled probe for molecular imaging and use thereof |
| EP2862857A1 (en) * | 2013-10-18 | 2015-04-22 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| DE202014011600U1 (de) | 2013-10-18 | 2023-05-31 | Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts | Markierte Inhibitoren des prostataspezifischen Membranantigens (PSMA), deren Verwendung als bildgebende Mittel und pharmazeutische Wirkstoffe für die Behandlung von Prostatakrebs |
| WO2015073678A1 (en) * | 2013-11-14 | 2015-05-21 | Endocyte, Inc. | Compounds for positron emission tomography |
| US10683272B2 (en) * | 2014-05-06 | 2020-06-16 | The Johns Hopkins University | Metal/radiometal-labeled PSMA inhibitors for PSMA-targeted imaging and radiotherapy |
| US10688200B2 (en) | 2015-12-31 | 2020-06-23 | Five Eleven Pharma Inc. | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
-
2016
- 2016-12-20 US US15/385,490 patent/US10688200B2/en active Active - Reinstated
- 2016-12-22 KR KR1020187021593A patent/KR20180098373A/ko not_active Application Discontinuation
- 2016-12-22 JP JP2018534552A patent/JP6850027B2/ja active Active
- 2016-12-22 CA CA3010295A patent/CA3010295C/en active Active
- 2016-12-22 EP EP16882430.8A patent/EP3397968B1/en active Active
- 2016-12-22 MX MX2018008168A patent/MX2018008168A/es unknown
- 2016-12-22 DK DK16882430.8T patent/DK3397968T3/da active
- 2016-12-22 CN CN201680079844.7A patent/CN108541302B/zh active Active
- 2016-12-22 SG SG11201805380YA patent/SG11201805380YA/en unknown
- 2016-12-22 WO PCT/US2016/068327 patent/WO2017116994A1/en active Application Filing
- 2016-12-22 EA EA201891544A patent/EA201891544A1/ru unknown
- 2016-12-22 AU AU2016380151A patent/AU2016380151A1/en not_active Abandoned
-
2018
- 2018-06-28 IL IL260342A patent/IL260342A/en unknown
- 2018-11-09 HK HK18114343.5A patent/HK1255215A1/zh unknown
-
2023
- 2023-06-13 AU AU2023203682A patent/AU2023203682A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018008168A (es) | 2019-02-20 |
| EA201891544A1 (ru) | 2018-11-30 |
| HK1255215A1 (zh) | 2019-08-09 |
| EP3397968A4 (en) | 2019-11-27 |
| DK3397968T3 (da) | 2021-11-01 |
| WO2017116994A1 (en) | 2017-07-06 |
| JP2019508374A (ja) | 2019-03-28 |
| EP3397968A1 (en) | 2018-11-07 |
| CN108541302A (zh) | 2018-09-14 |
| IL260342A (en) | 2018-08-30 |
| US10688200B2 (en) | 2020-06-23 |
| CA3010295C (en) | 2023-09-26 |
| EP3397968B1 (en) | 2021-09-29 |
| KR20180098373A (ko) | 2018-09-03 |
| JP6850027B2 (ja) | 2021-03-31 |
| AU2023203682A1 (en) | 2023-07-06 |
| AU2016380151A1 (en) | 2018-07-19 |
| CN108541302B (zh) | 2023-02-14 |
| US20170189568A1 (en) | 2017-07-06 |
| CA3010295A1 (en) | 2017-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201805380YA (en) | Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201808582RA (en) | Pyrrolotriazine compounds as tam inhibitors | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201803686UA (en) | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201805645QA (en) | Lsd1 inhibitors | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201408821SA (en) | Selective pi3k delta inhibitors | |
| SG11201407900WA (en) | Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201803627XA (en) | N-substituted indole derivatives as pge2 receptor modulators | |
| SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers | |
| SG11201402986RA (en) | Kinase inhibitors | |
| SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS |